Document is current
Any future updates will be listed below
-
Authors
Panasci, Justin https://orcid.org/0009-0003-1942-3572
Park, Changsu Lawrence
Tran, Ben https://orcid.org/0000-0001-9124-354X
Siu, Lillian L. https://orcid.org/0000-0002-3500-0540
- License Information
-
More Information
Article History
Received: 29 December 2025
Revised: 12 March 2026
Accepted: 9 April 2026
First Online: 27 April 2026
Competing interests
: The authors declare the following competing interests: LLS reports consultant (self) for Merck, Roche, Voronoi, GSK, Pfizer, Arvinas, Navire, Relay, Daiichi Sankyo, Amgen, Pangea, Tubulis, LTZ Therapeutics, Marengo, AstraZeneca, Incyte, Gilead, Bristol-Myers Squibb, Systimmune, EMD Serono, Break Through Cancer; grant/research support (institution) from Bristol-Myers Squibb, Roche/Genentech, GSK, Merck, Novartis, Pfizer, AstraZeneca, Boehringer-Ingelheim, Bayer, Amgen, Abbvie, EMD Serono, Daiichi Sankyo, Gilead, Marengo, Incyte, Loxo/Lilly, Takara and Tubulis; and ownership (spouse) for Treadwell Therapeutics (co-founder). BT reports consultant for Amgen, Astellas, AstraZeneca, Bayer, BMS, Ipsen, IQVIA, Janssen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Tolmar; honorarium from Amgen, Astellas, AstraZeneca, Bayer, BMS, Ipsen, Janssen, Merck, MSD, Pfizer, Sanofi, Tolmar; and grant/research support from Amgen, Astellas, AstraZeneca, Bayer, BMS, Genentech, Ipsen, Janssen, Pfizer, Movember, MSD.
